---
created: 2025-04-13
updated: 2025-04-13T10:53
id: EV3v-((@sf
specialty: pharmaco
specialty_id: 496
tags:
  - source/ak-original-decks::step-1::lolnotacop::drugs
  - "source/ak-step1-v11:": 
  - theme/b&b::11-hematology::04-cancer-drugs::06-other-cancer-drugs
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::bevacizumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::19-bevacizumab
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::07-immunology
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::22-onc-drugs::12-bevacizumab
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::11-oncology::bevacizumab
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::03-kinase-inhibitors-&-monoclonal-antibodies::02-rituximab,-cetuximab,-bevacizumab,-alemtuzumab,-trastuzumab"
type: flashcard
---

# Question
Which antitumor monoclonal antibody has an increased risk of bleeding and thromboembolism?   **bevacizumab**

---

# Answer
due to it inhibiting VEGF - BeVacizumab inhibits Blood Vessel formation